CryoLife Inc. (NYSE:CRY) shares reached a new 52-week high during trading on Monday . The stock traded as high as $16.27 and last traded at $16.20, with a volume of 242,478 shares traded. The stock had previously closed at $15.67.

Several research analysts have commented on CRY shares. Zacks Investment Research raised CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 price target on the stock in a research report on Friday, August 12th. Lake Street Capital started coverage on CryoLife in a research report on Wednesday, June 15th. They set a “buy” rating and a $15.00 price target on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of CryoLife in a research report on Tuesday, July 26th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $16.00 price target on shares of CryoLife in a research report on Wednesday, July 27th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. CryoLife presently has an average rating of “Buy” and a consensus target price of $15.00.

The stock’s 50-day moving average price is $14.21 and its 200-day moving average price is $12.18. The company has a market cap of $547.81 million and a price-to-earnings ratio of 51.47.

CryoLife (NYSE:CRY) last issued its earnings results on Monday, July 25th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.11. During the same period in the previous year, the company earned $0.03 EPS. The company earned $47.10 million during the quarter, compared to analysts’ expectations of $35.50 million. CryoLife’s quarterly revenue was up 32.6% on a year-over-year basis. On average, equities research analysts forecast that CryoLife Inc. will post $0.24 EPS for the current year.

In related news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the completion of the transaction, the director now owns 103,586 shares of the company’s stock, valued at $1,450,204. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.